Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-317-9 | CAS number: 1120-71-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
1,3-Propanesultone has been found to be carcinogenic in rats and mice by any of several routes of administration (i.e. oral, dermal, subcutaneous, i.v., transplacental).
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1970
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- - rats were treated orally by gavage once weekly at 30 mg/kg bw for 340 days
- GLP compliance:
- no
- Species:
- rat
- Strain:
- other: BD
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- no data
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 3% - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- - 340 days
- Frequency of treatment:
- - once weekly
- Post exposure period:
- - all animals were exposed untill death
- Dose / conc.:
- 30 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- - 12 animals were used
- Details on study design:
- - Dose selection rationale: 30 mg/kg bw (8.5% of LD50), since a low oral absorption has been expected
- Observations and examinations performed and frequency:
- - no data, only formation of tumors and mortality was described in the publication
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Details on results:
- CLINICAL SIGNS AND MORTALITY
- 2/12 animals died ahead of time
- 4/10 animals died between day 248 and 377 due to malignant tumors (2 in the nervous system, 1 subcutaneous, 1 nephroblastoma)
GROSS PATHOLOGY
- a few malignant tumours in remote organs were observed - Dose descriptor:
- NOAEL
- Based on:
- test mat.
- Sex:
- not specified
- Basis for effect level:
- histopathology: neoplastic
- Remarks on result:
- not determinable
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 451 (Carcinogenicity Studies)
- Deviations:
- not applicable
- GLP compliance:
- no
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River CD male and female rats were procured as weanlings from Charles River Breeding Laboratories
- Housing: 2 per large plastic cage (12 inches x l4 inches x 7 inches), on corncob bedding
- Diet: Wayne Lab Blox meal
- Water: ad libitum
- Acclimation period: 7 - 10 days of quarantine
ENVIRONMENTAL CONDITIONS
- animal rooms were air-conditioned - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- solutions (in water) were freshly prepared on the day of administration
VEHICLE
- water - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- - first group (low dose): 60 weeks exposure, 60 weeks on study
- second group (high dose): 32 weeks exposure, 60 weeks on study - Frequency of treatment:
- - twice weekly
- Post exposure period:
- - all rats were necropsied after 60 weeks
- Dose / conc.:
- 28 mg/kg bw/day (nominal)
- Dose / conc.:
- 56 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- - 26
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: the high dose correseponded to the experimentally determined MTD (acute, subacutly or subchronic pre-tests)
Because of the numerous mammary tumors developing in the females at the 18th week and the high mortality in males, administration of the high dose was discontinued at the 32nd week - Positive control:
- N-2-fluorenylacetamide
- Observations and examinations performed and frequency:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: twice daily, 7 days a week, for toxicologic effects or deaths
- presence of palpable masses was noted during such inspections
BODY WEIGHT: Yes
- Time schedule for examinations: weekly during the initial month of the study and biweekly thereafter
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- determined during the initial week and the fourth week of each subsequent 4-week period
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
- Moribund rats and those with large tissue masses were killed during the course of the chronic study. In addition, at the end of dosing, 5 animals of each sex from the group on the higher dose were killed and necropsied, and stained sections of the tissues were examined microscopically to detect any changes. These animals were used for calculation of tumor incidence but not survival rate .
- All rats were necropsied and the tissues examined histopathologically .
- the following tissues were examined routinely :
cerebrum, cerebellum, pituitary gland, spinal cord plus vertebrae, lung, heart, mediastinum, thymus, thyroid gland, parathyroid gland,
liver, spleen, pancreas, adrenal gland, kidney, urinary bladder, ovary, uterus or testis, accessory sex organ, esophagus, stomach, intestinal tract, and any abnormal tissue or mass . - Statistics:
- Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier, which is commonly called the "life table method." Animals were statistically censored as of the time they died of other than natural causes or were found to be missing. For statistical analyses of a possible dose-related effect on survival, the method of Cox for testing 2 groups of equality and Tarone's extensions of Cox's methods for testing for a dose-related trend were used.
One-tailed P-values were reported for all tests except the departure from linearity test, which was only reported when its two-tailed P-value was less than 0.05. Also, the one-tailed Fisher's exact probability test and the Cochran-Armitage test for linear trend in proportions, with continuity correction were used. The treated groups were always compared to a "matched" negative or vehicle control, as appropriate. - Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- At the 45th week animals on the low dose began showing signs of central nervous system disturbances. Therefore, the experiment was terminated at the 60th week.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Propanesultone caused high mortality, and only 4 males and 6 females survived at 52 weeks at the high-dose level.
- Body weight and weight changes:
- not specified
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Propanesultone was tested at a sufficiently high dose to be toxic, but not enough animals survived to assess its potential for inducing late-appearing tumors. However, the treated animals of each sex had a highly significant incidence of malignant glioma of both the cerebrum and the cerebellum at each dose level (see table). In addition, each dose group of female rats had a significantly elevated incidence of mammary adenocarcinoma. A somewhat elevated incidence of granulocytic leukemia was found in each sex. Incidence of adenocarcinomas of the small intestine was 4 - 12% in the treated animals of each sex, but was zero in the controls. Two squamous cell carcinomas of the ear duct occurred in the male rats and 2 occurred in the female rats, but none developed in the matched or pooled controls. All of these cancers are rarely found in negative control animals.
- Details on results:
- Propanesultone caused high mortality, and only 4 males and 6 females survived at 52 weeks at the high-dose level. Because of the numerous mammary tumors developing in the females at the 18th week and the high mortality in males, administration of the high dose was discontinued at the 32nd week.
At the 45th week animals on the low dose began showing signs of central nervous system disturbances. Therefore, the experiment was terminated at the 60th week.
Propanesultone was tested at a sufficiently high dose to be toxic, but not enough animals survived to assess its potential for inducing late-appearing tumors. However, the treated animals of each sex had a highly significant incidence of malignant glioma of both the cerebrum and the cerebellum at each dose level (see table). The gliomas were astrocytomas and were often detected grossly as pea-sized areas of discoloration in the cerebrum or cerebellum. In addition, each dose group of female rats had a significantly elevated incidence of mammary adenocarcinoma. A somewhat elevated incidence of granulocytic leukemia was found in each sex. Incidence of adenocarcinomas of the small intestine was 4 - 12% in the treated animals of each sex, but was zero in the controls. Two squamous cell carcinomas of the ear duct occurred in the male rats and 2 occurred in the female rats, but none developed in the matched or pooled controls.
All of these cancers are rarely found in negative control animals. Thus propanesultone induced significant increases in malignant gliomas and mammary adenocarcinomas, and the incidences of leukemia, cancer of the small intestine, and squamous cell carcinoma of the ear duct were increased over those in controls. - Dose descriptor:
- NOAEL
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- histopathology: neoplastic
- Remarks on result:
- not determinable
- Dose descriptor:
- T25
- Remarks:
- (daily exposure for 104 weeks)
- Effect level:
- 1.6 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: neoplastic
- Dose descriptor:
- T25
- Remarks:
- (adapted to workplace situation)
- Effect level:
- 4.48 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: neoplastic
Referenceopen allclose all
Tumour frequency in rats after administration of 1,3 propanesultone for 60 or 32 weeks by gavage:
Tumour type |
0 mg/kg |
28 mg/kg (60 weeks) |
56 mg/kg (32 weeks) |
|||
|
Males |
Females |
Males |
Females |
Males |
Females |
|
|
|
|
|
|
|
Cerebrum Malignant Glioma |
1/16 (6 %) |
1/16 (6 %) |
10/26 (38 %) |
12/26 (46 %) |
11/26 (42 %) |
12/26 (46 %) |
Cerebellum Malignant Glioma |
0/16 (0 %) |
0/16 (0 %) |
6/26 (23 %) |
8/26 (31 %) |
11/26 (42 %) |
4/26 (15 %) |
Mammary gland Adenocarcinoma |
|
0/16 (0 %) |
|
6/26 (23 %) |
|
13/26 (50 %) |
Leukemia | 0/16(0 %) | 0/16(0 %) | 0/28(0 %) | 2/26(8 %) | 4/26(15 %) | 3/26(12 %) |
Small intestine carcinoma | 0/16 (0 %) |
0/16(0 %) | 3/26(12 %) | 2/26(8 %) | 3/26(12 %) | 1/26(8 %) |
T25 deviation according to Norwegian Pollution Control Authority:
Lowest dose with a significant increased tumor incidence:
The highest incidence of malignancies at the lowest dose level (i.e. in the cerebrum in females) is used.
Control: 1/16 (6 %)
28 mg/kg bw: 12/26 (46 %)
net %: [12 x (100/26) – 1 x (100/16)]/[100-1 x (100/16)] = 43%
Daily dose per kg bodyweight during the exposure period:
28 mg/kg bw, twice per week: i.e. 8.0 mg/kg bw/day
Dose of this incidence of gliomas when administration started after 6 weeks and exposure is for 24 months:
60/104 x 60/104 x 8.0 mg propanesultone/kg bw/day = 2.7 mg propanesultone/kg bw/day
T25 after 24 months (daily exposure):
T25 = 25/43 x 2.7 mg/kg bw/day = 1.6 mg/kg bw/day
Adaptation to workplace situation (exposure for 5 days/week, 48 weeks/year over 40 years):
T25(oral, workplace) = 1.6 mg/kg bw/d x 7/5 x 52/48 x 75/40 = 4.48 mg/kg bw/d
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- T25
- 4.48 mg/kg bw/day
- Species:
- rat
- Quality of whole database:
- Studies meets generally accepted scientific principles, acceptable for assessment.
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Dose descriptor:
- T25
- 7.9 mg/m³
- Species:
- rat
- Quality of whole database:
- No study for the inhalation route available. Thus, the chronic oral gavage study in rats reported by Weisburger et al. (1981) has been used to derive an oral T25 value and to extrapolate to the inhalation exposure route.
Carcinogenicity: via dermal route
Link to relevant study records
- Endpoint:
- carcinogenicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1976
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The effects of limited and prolonged dermal exposure of mice to propanesultone were investigated with specific reference to the occurrence of skin and systemic neoplasia by applying the test solutions in different concentrations to the skin.
- GLP compliance:
- no
- Species:
- mouse
- Strain:
- other: CFI, C3H, CBah
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - mice of three strains were used: CF1 (an albino strain derived from Carworth Farm No. 1), C3H (obtained from the Laboratory Animal Centre, Carshalton) and CBah (a "hairless" strain derived from the Chester Beatty Institute, London).
- mice were bred in specific pathogen- ree conditions at Tunstall Laboratory
- six weeks of age at the beginning of treatment
- water and cubed 86S diet (obtained from Grain Harvesters, Wingham, Kent) were provided ad libitum
Animals for the comparative long-term study:
The mice were caged in groups of 5, of the same sex and strain, each receiving the same treatment.
Animals for the limited exposure study:
The mice (CFI) were individually housed. - Route of administration:
- dermal
- Vehicle:
- other: benzene or toluene
- Details on exposure:
- Comparative long-term study:
The backs of the CF1 and C3H mice were shorn with fine electric clippers prior to the first treatment and then once weekly for the duration of the experiment. The test solutions and solvents were applied to the skin with fine brushes, twice weekly for 56 weeks. The volume applied on each occasion was estimated to be 0.05 - 0.1 mL/mouse. There were four treatment groups in each strain (CFI, C3H and CBah):
1) 2.5% w/v propanesultone in benzene for 4 weeks then in toluene for 1 year
2) 2.5 % w/v ß-propiolactone in benzene for 4 weeks then in toluene for 1 year
3) benzene for 4 weeks then toluene for 1 year
4) shorn only with no chemical exposure
Limited exposure study:
The hair on the back was shorn with fine electric clippers before treatment started and, then, weekly for the 78-week test period.
Treatment of all mice in a single block was started on the same day. The test solutions (0.1 mL) were applied to the dorsal skin using all-glass syringes. The treatment regimes were as follows:
1) one application of toluene; thereafter no further treatment
2) one application of 2.5% w/v propanesultone in toluene; thereafter no further treatment
3) 10 applications of 2.5 % w/v propanesultone in toluene on alternate days; thereafter no further treatment
4) one application of 25 % w/v propanesultone in toluene; thereafter no further treatment - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Comparative long-term study:
- 56 weeks (one application, treatment group 1,2 and 4)
Limited exposure study:
- 19 days (treatment group 3) - Frequency of treatment:
- Comparative long-term study:
- twice weekly
Limited exposure study:
- one single treatment (group 1, 2, 4) and 10 applications on alternate days (group 3) - Post exposure period:
- - Comp. long-term study: end of treatment until week 58
- Lim. exposure study: end of treatment until week 78 - Dose / conc.:
- 2.5 other: % (nominal)
- Remarks:
- Comp. long-term study and Lim. exposure study
- Dose / conc.:
- 25 other: % (nominal)
- Remarks:
- Lim. exposure study
- No. of animals per sex per dose:
- Comparative long-term study:
- 25 males and 25 females of each strain per group
Limited exposure study:
- 48 males and 48 females per group - Observations and examinations performed and frequency:
- Comparative long-term study:
Records were kept of the gross appearance of the treated skins.
Limited exposure study:
Each animal was examined weekly and the size, appearance and position of all skin lesions were recorded. The criteria used for the initial recording of the presence of a skin tumour were that the lesion had reached a diameter of 2 mm and had persisted for 2 weeks. As a measure of the rate of tumour growth, the times when tumours reached 6 mm and 10 mm respectively were also recorded. - Sacrifice and pathology:
- Comparative long-term study:
All mice that died, unless autolysis was too advanced, and all survivors, killed at the end of the study, were subjected to a detailed necropsy with a histological examination of the skin and major organs.
Limited exposure study:
After 78 weeks, the mice were killed and subjected to a detailed necropsy and a histological examination of skin and the major viscera for the presence of neoplasms. Similar examinations were carried out on animals dying or killed because of ill-health during the experiment, with the exception of
those not surviving beyond the first 7 days after exposure.
Both studies:
Skin tumours were classified on histological criteria as benign or malignant including probably malignant epithelial tumours. The epidermal tumours seen were papillomas, basal cell carcinomas, carcinomas and adenomas of adnexae, and squamous cell carcinomas. The dermal tumours found were fibromas, fibrosarcomas, haemangiomas, haemangiosarcomas and myxosarcomas.
Some epidermal tumours regressed spontaneously and could not be examined histologically. For the purpose of statistical analysis, such tumours, provided that they had reached a diameter of 2 mm and had persisted for 2 weeks, were classified as papillomas. Similarly, a tumour diagnosed as malignant was deemed to have become malignant at the time when it reached a diameter of 10 mm or, when the animal bearing it died, if this size had not been attained. - Statistics:
- Actuarial analyses were carried out on both skin and systemic tumour data. For each class of tumour (e.g. 2 mm skin tumours, systemic lung tumours) the significance of the number of tumours occurring in the treatment groups was obtained by testing against the expected incidence, using a Chi 2 statistic. Lifetables were constructed for the incidence of 2 mm and malignant tumours in the 25 % propane sultone treatment group in the limited exposure study. Similar analyses were carried out on the data from the comparative longterm study, although only the length of survival was available to carry out the age-adjusted analysis.
Reference
Comparative long-term study
Survival:
In all control groups, the survival to the end of the trial (58 weeks) was 60%, or higher. This contrasts with the treated mice of all three strains exposed to propane sultone, where survival was much less. No CF1 of C3H mice survived exposure to propane sultone for 58 weeks, while only 12 % of the CBah mice exposed to propane sultone survived for 58 weeks.
Skin tumours:
No tumours were seen in the untreated and solvent controls whereas animals of all three strains exposed to propane sultone developed tumours of the dorsal treated skin. Tumours of both the epidermis and dermis were identified histologically, the majority being of epidermal origin, except in the C3H males, where the predominant tumour type was a dermal fibrosarcoma.
There was an apparent difference between strains in the number of animals ultimately developing skin tumours after repeated skin application of propane sultone; 40% of the CF1, 55% of the C3H and 79% of the CBah strain. Apparent differences were observed between the sexes in two strains in terms of skin tumour response to propane sultone exposure, with 71% of the CF1 males and 91% of C3H males having tumours compared to 12% and 24% of the females respectively. In contrast, in the CBah strain 87% of the males and 72% of the females developed skin tumours. However, the low incidences of tumours in CF1 and C3H females were associated with poor survival. When an actuarial analysis of the tumour risk is performed, which makes an allowance for differences in survival, the apparent strain and sex differences could not be confirmed.
Systemic tumours:
Systemic neoplasms were classified as tumours of the lympho-reticular tissues, the lung, female reproductive system and other tumours. The tumour incidence is given in the table below. There was a significant increase in the incidence of lympho-reticular cell sarcomas in CF1 mice exposed to propane sultone. C3H females treated with propane sultone had a higher incidence of tumours of the mammary gland and uterus than had the control C3H females. At necropsy, some animals, both in control and treated groups, had grossly enlarged spleens. Histologically, this was associated with an intense proliferation of myeloid elements in the red pulp of the affected animals.
Limited exposure study
Survival:
During the first 4 days of the study, 12 males and 2 females died after exposure to a single dose of a 25% w/v solution of propane sultone in toluene. This finding is consistent with the known acute toxicity of propane sultone. The number of survivors to the end of trial was significantly less in all treatment groups than in the solvent controls, with the exception of males exposed to a single application of a 2.5% w/v solution. No mice survived for 78 weeks after exposure to a single application of the 25% w/v solution. Ten applications of the 2.5% w/v solution resulted in no females and only 8% males surviving for 78 weeks. Females exposed to a single application of a 2.5% w/v solution had a 44% survival rate, whereas the males given this single dose had a survival rate comparable to that of the controls.
Skin tumours.
No skin tumours were found in any of the solvent-treated control CFl mice. There was a highly significant increase in the incidence of tumours of the treated skin in mice surviving the initial toxic effects of exposure to a Single application of a 25% w/v solution of propane sultone. A not uncommon clinical finding in these animals was ulceration seen shortly after application of the dose. These lesions healed subsequently with scarring. 29 out of 36 males and 26 out of 46 females developed tumours and 70% of these tumours were papillomas. The other skin tumours were either carcinomas or sarcomas, many of them being highly anaplastic. Single or ten sequential applications on alternate days of a 2.5% w/v solution caused a minimal, but not statistically significant, increased incidence of tumours at the site of application. Most of the tumours were first recorded 4 - 10 weeks after exposure and many reached diameters of 2 - 3 cm after a growth period of 3 - 5 weeks. About half the total number of tumours that developed underwent complete spontaneous regression and were therefore classified as papillomas for the purposes of statistical analysis. Several tumours with an initial rapid growth rate showed ischaemia and sloughing of the external mass, which was followed by regrowth at the primary site. Histologically, these proved to be malignant. Metastases to local and distant sites occurred in two males with anaplastic carcinomas and in three females with fibrosarcomas. To assess the probability of skin tumours developing in male and female mice after a single application of a 25% w/v solution of propane sultone, the data on the growth rates of individual tumours were analysed. During the period from 0 - 8 weeks for 2 mm tumours and 0 - 30 weeks for malignant tumours, the lifetables were similar for both sexes. After these periods, the risk to the male increased for both categories of tumours, whereas the risk to the females remained steady.
Systemic tumours:
Systemic neoplasms were classified as tumours of the lympho-reticular tissues and the lung, with all other tumours grouped under one heading since no specific tumour type made a predominant contribution to the total. Exposure of males and females to a single application of a 25% w/v solution or to 10 applications of 2.5% w/v solution resulted in a significant increase in the risk of tumour development for all three categories of systemic tumours, the latter dosage regime producing the greater risk. The single application of the 2.5% w/v solution increased the risk in females of developing lung or other tumours, but this risk was not realised in males having a similar exposure.
Table 1: Incidence of skin tumours in three strains of mice after repeated skin application of Propane sultone (2.5% w/v solutions) for 56 weeks
Treatment |
Strain |
Group size |
Number of animals with tumours |
Total number of animals with tumours |
|||
|
|
|
Benign |
|
Malignant |
|
|
|
|
|
With one tumour |
With more than one tumour |
With one tumour |
With more than one tumour (incl. benign) |
|
Untreated |
CFl Males |
24 |
|
|
|
|
0 |
|
Females |
23 |
|
|
|
|
0 |
|
C3H Males |
25 |
|
|
|
|
0 |
|
Females |
20 |
|
|
|
|
0 |
|
CBah Males |
25 |
|
|
|
|
0 |
|
Females |
25 |
|
|
|
|
0 |
Solvents |
CFl Males |
22 |
|
|
|
|
0 |
|
Females |
25 |
|
|
|
|
0 |
|
C3H Males |
25 |
|
|
|
|
0 |
|
Females |
21 |
|
|
|
|
0 |
|
CBah Males |
24 |
|
|
|
|
0 |
|
Females |
25 |
|
|
|
|
0 |
Propane sultone |
CFl Males |
21 |
6 |
|
6 |
3 |
15 |
|
Females |
24 |
3 |
|
|
|
3 |
|
C3H Males |
22 |
1 |
1 |
16 |
2 |
20 |
|
Females |
25 |
2 |
|
3 |
1 |
6 |
|
CBah Males |
23 |
2 |
|
18 |
|
20 |
|
Females |
25 |
2 |
1 |
13 |
2 |
18 |
Table 2: Incidence of systemic tumours in three strains of mice after repeated skin application of Propanesultone (2.5% w/v solutions) for 56 weeks
Treatment |
Strain |
Group size |
Number of animals in each classifcation |
|||||
|
|
|
Lympho-reticular |
Lung |
Reproductive system |
Other |
With at least one tumour |
With more than one tumour |
Untreated |
CFl Males |
24 |
1 |
5 |
|
1 |
7 |
|
|
Females |
23 |
1 |
2 |
1 |
|
4 |
|
|
C3H Males |
25 |
|
|
|
16 |
16 |
|
|
Females |
20 |
|
|
1 |
|
1 |
|
|
CBah Males |
25 |
|
|
|
4 |
4 |
|
|
Females |
25 |
|
|
|
|
0 |
|
Solvents |
CFl Males |
22 |
|
4 |
|
3 |
7 |
|
|
Females |
25 |
3 |
4 |
1 |
|
7 |
1 |
|
C3H Males |
25 |
1 |
|
|
12 |
12 |
1 |
|
Females |
21 |
|
|
2 |
2 |
4 |
|
|
CBah Males |
24 |
|
|
|
2 |
2 |
|
|
Females |
25 |
|
|
|
1 |
1 |
|
Propane sultone |
CFl Males |
21 |
12 |
9 |
|
|
18 |
3 |
|
Females |
24 |
17 |
2 |
2 |
|
18 |
2 |
|
C3H Males |
22 |
2 |
5 |
|
11 |
13 |
4 |
|
Females |
25 |
2 |
1 |
18 |
1 |
17 |
5 |
|
CBah Males |
23 |
2 |
|
|
1 |
3 |
|
|
Females |
25 |
2 |
|
5 |
|
6 |
1 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- T25
- 9.96 mg/kg bw/day
- Species:
- rat
- Quality of whole database:
- Study meets generally accepted scientific principles. However, it is not suitable to derive a T25 value. Thus, the chronic oral gavage study in rats reported by Weisburger et al. (1981) has been used to derive an oral T25 value and to extrapolate to the dermal exposure route.
Mode of Action Analysis / Human Relevance Framework
Justification for classification or non-classification
Based on the available data regarding carcinogenicity 1,3-propanesultone is subject to classification and labelling:
Carc. 1B, H350 according to Regulation 1272/2008/EC.
Additional information
Animal data
1,3-propanesultone is a highly reactive alkylating agent. Its carcinogenic potency has been demonstrated in several studies in mice and rats.
In the key study with Charles River CD rats (Weisburger et al., 1981) 28 mg or 56 mg 1,3-propanesultone per kg bodyweight were administered by gavage two times per week. The low dose was administered for 60 weeks, while the high dose was given for 32 weeks and the animals were killed 28 week later (weighted mean dose was 29.9 mg/kg bw). Both doses led to various types of malignant tumors, primarily tumors of the brain with a possibility of induction of leukemia and carcinomas of the small intestine (see table below).
Tumour frequency in rats after oral administration of 1,3-propansultone.
Tumour type |
0 mg/kg |
28 mg/kg (60 weeks) |
56 mg/kg (32 weeks) |
|||
|
Males |
Females |
Males |
Females |
Males |
Females |
|
|
|
|
|
|
|
Cerebrum Malignant Glioma |
1/16 (6 %) |
1/16 (6 %) |
10/26 (38 %) |
12/26 (46 %) |
11/26 (42 %) |
12/26 (46 %) |
Cerebellum Malignant Glioma |
0/16 (0 %) |
0/16 (0 %) |
6/26 (23 %) |
8/26 (31 %) |
11/26 (42 %) |
4/26 (15 %) |
Mammary gland Adenocarcinoma |
|
0/16 (0 %) |
|
6/26 (23 %) |
|
13/26 (50 %) |
Leukemia | 0/16 (0 %) | 0/16 (0 %) | 0/28 (0 %) | 2/26 (8 %) | 4/26 (15 %) | 3/26 (12 %) |
Small intestine carcinoma | 0/16 (0 %) |
0/16 (0 %) | 3/26(12 %) | 2/26(8 %) | 3/26(12 %) | 1/26(8 %) |
Oral treatment of rats via gavage once weekly at 30 mg/kg bw/day for 340 days revealed a few malignant tumours in remote organs (nervous system, subcutaneous, nephroblastoma (Druckrey, 1970).
Doak et al. (1976) investigated the carcinogenic activity of 1,3-propanesultone by skin painting. Application of a 2.5% (w/v) solution of 1,3-propanesultone in benzene, twice weekly for 4 weeks, followed by application of a 2.5% (w/v) solution in toluene, twice weekly for 1 year, to the skin of CFI, C3H or CBah mice (groups of 21 - 25 mice per sex, 140 mice in total) led to the development of skin tumours in 59% of the mice (33 carcinomas, 32 sarcomas, 21 papillomas, 6 probably malignant tumours, 1 fibroma). Systemic tumours were observed in 51% of the mice consisting of 36 lymphosarcomas and 1 reticulosarcoma of the spleen, 11 hepatomas, 17 lung tumours and 27 other tumours. In 26 animals myeloid hyperplasia was noted.
Applied once to the skin of CFI mice, the 2.5% solution of 1,3-propanesultone in toluene caused enlargement of the spleen, thymus or lymph nodes in 2/48 males and 7/48 females but did not induce skin tumours within the 78-week observation period.
When the same concentration was applied to mouse skin ten times, the spleen, thymus and lymph nodes were enlarged in 19/48 males and 35/48 females. Skin tumours developed by week 4 in 5/48 males and 2/48 females. After a single dermal application of 0.1 mL of a 25% (w/v) solution of 1,3-propanesultone in toluene (corresponding to approximately 830 mg/kg bw/d) skin tumours developed in 29/36 males and 26/46 females. The first epidermal papillomas developed within 5 weeks and most developed within 10 weeks. At the same time, spleen, thymus and lymph nodes were enlarged. During the first 4 days 14/96 (15%) animals died; autopsy of these animals was not carried out.
Overall, the incidence of local and systemic tumours was much higher after chronic treatment than after single or short term treatment.
Subcutaneous injection of 1,3-propanesultone in rats yielded injection-site sarcomas (Druckrey et al., 1970). A single subcutaneous dose of 100 mg/kg produced local sarcomas in all of 18 treated rats (Druckrey et al., 1970). A single intravenous bolus of 150 mg/kg in 32 rats caused the death of 1 rat with a brain tumor after 235 days and the death of 9 others with malignant tumors of a variety of sites within 459 days (Druckrey et al., 1970). A single intravenous dose of 20 mg/kg given to pregnant rats on day 15 of gestation produced malignant neurogenic tumors in their offspring (Druckrey et al., 1970).
Human data
1,3 -propanesultone is only industrially used where rigorous risk management measures are in place during production and use. Therefore, human exposure can principially excluded and consequently, no epidemiological data on 1,3-propanesultone is available. However, during manufacturing mainly in the 1950s and 1960s exposure of a limited amount of workers could have occurred and the medical history of some cases could be traced (Bolt and Golka, 2004). As cerebral gliomas are the main systemic tumours induced by 1,3-propanesultone experimentally, the occurrence of a glioblastoma among previously exposed persons appears conspicuous. Three intestinal malignancies were recorded among the cases observed. Also noteworthy is one case of a duodenal carcinoma, normally a rare human malignancy. Two haematopoietic/lymphatic malignancies of different nature have been observed, and there was one case of a renal cell carcinoma. These malignancies observed within a group of persons exposed to 1,3-propanesultone appear consistent with the expectations from the available animal studies.
Derivation of T25 values
The dermal study in mice (Doak et al., 1976) is not suitable to derive a T25 value as only a 2.5% solution of 1,3-propanesultone was tested and the corresponding dose in mg/kg bw is unknown. Moreover, 1,3-propanesultone was dissolved in toluene which is classified for skin irritation. Observations focused on mortality and tumour formation, whereas skin reactions were not examined. Consequently, skin irritation might have occurred during the 1-year dermal application, influencing the local and systemic tumour incidence due to local inflammation or the enhancement of dermal absorption.
Thus, the chronic oral gavage study in rats reported by Weisburger et al. (1981) has been used in the following to derive an oral T25 value and to extrapolate to the dermal and inhalation exposure route.
Lowest dose with a significant increased tumor incidence:
The highest incidence of malignancies at the lowest dose level (i.e. in the cerebrum in females) is used.
Control: 1/16 (6%); 28 mg/kg bw dose group: 12/26 (46%)
net %: [12 x (100/26) – 1 x (100/16)]/[100 -1 x (100/169)] = 43%
Daily dose per kg bodyweight during the exposure period: 28 mg/kg bw, twice per week: i.e. 8.0 mg/kg bw/day
Dose of this incidence of gliomas when administration started after 6 weeks and exposure is for 24 months:
60/104 x 60/104 x 8.0 mg 1,3-propanesultone/kg bw/day = 2.7 mg 1,3 -propanesultone/kg bw/day
T25(oral) after daily exposure for 104 weeks: T25(oral) = 25/43 x 2.7 mg/kg bw/day = 1.6 mg/kg bw/day
This T25 value is identical with the value established by the Norwegian Pollution Control Authority in 1997. This value reflects daily exposure for 104 weeks and has to be adapted to the workplace situation (exposure for 5 days/week, 48 weeks/year over 40 years):
T25(oral, workplace) = 1.6 mg/kg bw/d x 7/5 x 52/48 x 75/40 = 4.48 mg/kg bw/d.
The oral T25 value of 4.48 mg/kg bw/d is applied in the derivation of the dermal and inhalation T25 value.
In the absence of specific absorption data following oral, dermal or inhalation exposure, the acute toxicity data can be used to establish a factor for the oral-to-inhalation and oral-to-dermal route extrapolation.
The inhalation LC50 in the rat after a 6-hour exposure is approximately 1.7 mg/L (OTS, 1992). Taking into account a rat breathing volume of 0.29 m³/kg bw and assuming 100% absorption the corresponding systemic dose is 490 mg/kg bw. In comparison, oral LD50 values ranging between 100 and 350 mg/kg bw have been reported for the rat (OTS, 1992; MAK, 1985; Druckrey et al., 1970), indicating that inhalation absorption will not be higher than oral absorption. Thus, the factor of 1 for oral-to-inhalation extrapolation is justified.
The only species where both dermal and oral acute toxicity data are available is the mouse. Whereas the oral LD50 is 400 mg/kg bw (OTS, 1992), the dermal LD50 is > 830 mg/kg bw (830 mg/kg bw caused 15% death; Doak et al., 1972). This data indicates that dermal absorption will be more than 2-fold lower than oral absorption, justifying a factor of 0.5 for oral-to-dermal extrapolation.
Taking into account the T25 (oral, workplace) of 4.48 mg/kg bw/d, the 8-h standard respiratory volume of 0.38 m³/kg bw for the rat, the adjustment of the respiratory volume for light activity of 6.7 m³/10 m³ and the oral-to-inhalation route extrapolation factor of 1 the T25 (inhalation, workplace) can be calculated as:
T25 (inhalation, workplace) = 4.48 mg/kg bw/d / 0.38 m³/kg bw x 1 x 6.7 m³/10 m³ = 7.9 mg/m³
Taking into account the T25 (oral, workplace) of 4.48 mg/kg bw/d and the oral-to-dermal route extrapolation factor of 0.5 the T25 (dermal, workplace) can be calculated as:
T25 (dermal, workplace) = 4.48 mg/kg bw/d / 0.5 = 9.96 mg/kg bw/d.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.